Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 16/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5725637 | 0.80 | MEN1 (0.50) | KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL9860590 | 0.80 | SMN1; SMN2 (0.52) | KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL5726231 | 0.80 | KMT2A (0.53) | KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL5725306 | 0.79 | KMT2A (0.52) | KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL5725490 | 0.77 | TBXAS1 (0.41) | TBXAS1KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL9860310 | 0.76 | MEN1 (0.53) | KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL5726245 | 0.75 | KMT2A (0.49) | KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL9860360 | 0.75 | MEN1 (0.54) | KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL5726539 | 0.75 | KMT2A (0.45) | KMT2AMEN1LMNASMN1; SMN2LTA4H | |
| SCHEMBL8295973 | 0.73 | CYP2B6 (0.43) | TBXAS1KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1705169-A2 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | Hormos Medical Ltd. (FI) | 2006-09-27 | — | — | EP | disclosed |
| EP-1235776-B1 | TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | HORMOS MEDICAL CORP (FI) | 2006-02-08 | — | — | EP | disclosed |
| US-6875775-B2 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD (FI) | 2005-04-05 | — | — | US | disclosed |
| US-20030225130-A1 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD. | 2003-12-04 | — | — | US | disclosed |
| US-6576645-B1 | Such as 3-(4-chloro-1-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)--2-phenylbut-1 -enyl)phenol; producing tissue specific estro-genic and/or antiestrogenic effect | HORMOS MEDICAL OY LTD (FI) | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225130-A1 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | ESR2, ESR1, GPER1 | TBXAS1 2071/4885KMT2A 987/4885MEN1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.